OBJECTIVE: To describe the natural history of rheumatic manifestations of Ross River virus (RRV) disease. DESIGN: Prospective longitudinal clinical review. SETTING: North Queensland local government areas of Cairns, Douglas, Mareeba and Atherton during January to May 1998. PARTICIPANTS: General practice patients diagnosed with RRV disease on the basis of symptoms and a positive RRV IgM result. MAIN OUTCOME MEASURES: Rheumatic symptoms and signs assessed as soon as possible after disease onset and on two subsequent occasions (up to 6.5 months after onset). RESULTS: 57 patients were recruited, 47 of whom were reviewed three times (at means of 1.1, 2.4 and 3.6 months after disease onset). Results are reported for these 47: 46 (98%) complained of joint pain at first review, with the ankles, wrists, fingers, knees and metacarpophalangeal joints (II-IV) most commonly involved. Prevalence of joint pain decreased progressively on second and third reviews, both overall (92% and 68% of patients, respectively), and in the five joints most commonly affected. The prevalence of other common rheumatic symptoms and signs, and use of non-steroidal anti-inflammatory drugs, also progressively declined over the three reviews. CONCLUSIONS: Earlier studies may have overestimated the prevalence and duration of symptoms in RRV disease. Progressive resolution over 3-6 months appears usual.
OBJECTIVE: To describe the natural history of rheumatic manifestations of Ross River virus (RRV) disease. DESIGN: Prospective longitudinal clinical review. SETTING: North Queensland local government areas of Cairns, Douglas, Mareeba and Atherton during January to May 1998. PARTICIPANTS: General practice patients diagnosed with RRV disease on the basis of symptoms and a positive RRV IgM result. MAIN OUTCOME MEASURES: Rheumatic symptoms and signs assessed as soon as possible after disease onset and on two subsequent occasions (up to 6.5 months after onset). RESULTS: 57 patients were recruited, 47 of whom were reviewed three times (at means of 1.1, 2.4 and 3.6 months after disease onset). Results are reported for these 47: 46 (98%) complained of joint pain at first review, with the ankles, wrists, fingers, knees and metacarpophalangeal joints (II-IV) most commonly involved. Prevalence of joint pain decreased progressively on second and third reviews, both overall (92% and 68% of patients, respectively), and in the five joints most commonly affected. The prevalence of other common rheumatic symptoms and signs, and use of non-steroidal anti-inflammatory drugs, also progressively declined over the three reviews. CONCLUSIONS: Earlier studies may have overestimated the prevalence and duration of symptoms in RRV disease. Progressive resolution over 3-6 months appears usual.
Authors: Thomas E Morrison; Alan C Whitmore; Reed S Shabman; Brett A Lidbury; Suresh Mahalingam; Mark T Heise Journal: J Virol Date: 2006-01 Impact factor: 5.103
Authors: Kristina A Stoermer; Adam Burrack; Lauren Oko; Stephanie A Montgomery; Luke B Borst; Ronald G Gill; Thomas E Morrison Journal: J Immunol Date: 2012-09-12 Impact factor: 5.422
Authors: Ian Hickie; Tracey Davenport; Denis Wakefield; Ute Vollmer-Conna; Barbara Cameron; Suzanne D Vernon; William C Reeves; Andrew Lloyd Journal: BMJ Date: 2006-09-01
Authors: Weiqiang Chen; Suan-Sin Foo; Nestor E Rulli; Adam Taylor; Kuo-Ching Sheng; Lara J Herrero; Belinda L Herring; Brett A Lidbury; Rachel W Li; Nicole C Walsh; Natalie A Sims; Paul N Smith; Suresh Mahalingam Journal: Proc Natl Acad Sci U S A Date: 2014-04-14 Impact factor: 11.205
Authors: Liz J Walker; Linda A Selvey; Andrew Jardine; Cheryl A Johansen; Michael D A Lindsay Journal: Am J Trop Med Hyg Date: 2018-10 Impact factor: 2.345
Authors: Man-Koumba Soumahoro; Patrick Gérardin; Pierre-Yves Boëlle; Joelle Perrau; Adrian Fianu; Jacques Pouchot; Denis Malvy; Antoine Flahault; François Favier; Thomas Hanslik Journal: PLoS One Date: 2009-11-11 Impact factor: 3.240